Nariaki Asada

Nariaki Asada

Auto-generated profile, based on publicly available information

Nariaki Asada

III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2025 in Nature Immunology
Verified
Journal Article
Open access
PDF file
NANariaki Asada
Nariaki Asada
PGPauline Ginsberg
Pauline Ginsberg
HPHans-Joachim Paust
Hans-Joachim Paust
NSNing Song
Ning Song
JRJan-Hendrik Riedel
Jan-Hendrik Riedel
UPUlf Panzer
Ulf Panzer
Tissue-resident memory T (TRM) cells are a specialized T cell population that reside in tissues and provide a rapid protective response upon activation. Here, we showed that human and mouse CD4+ TRM cells existed in a poised state and stored messenger RNAs encoding proinflammatory cytokines without protein production. At steady state, cytokine mRNA translation in TRM cells was suppressed by the integrated stress response (ISR) pathway. Upon activation, the central ISR regulator, eIF2α, was dephosphorylated and stored cytokine mRNA was translated for immediate cytokine production. Genetic or pharmacological activation of the ISR–eIF2α pathway reduced cytokine production and ameliorated autoimmune kidney disease in mice. Consistent with these results, the ISR pathway in CD4+ TRM cells was downregulated in patients with immune-mediated diseases of the kidney and the intestine compared to healthy controls. Our results indicated that stored cytokine mRNA and translational regulation in CD4+ TRM cells facilitate rapid cytokine production during local immune response.

15 March 2023 in Science Translational Medicine
Verified
Journal Article
Open access
HPHans-Joachim Paust
Hans-Joachim Paust
NSNing Song
Ning Song
DFDonatella De Feo
Donatella De Feo
NANariaki Asada
Nariaki Asada
STSelma Tuzlak
Selma Tuzlak
UPUlf Panzer
Ulf Panzer
GM-CSF in glomerulonephritis: Despite glomerulonephritis being an immune-mediated disease, the contributions of individual immune cell types are not clear. To address this gap in knowledge, Paust et al . characterized pathological immune cells in samples from patients with glomerulonephritis and in samples from mice with the disease. The authors found that CD4+ T cells producing granulocyte-macrophage colony-stimulating factor (GM-CSF) licensed monocytes to promote disease by producing matrix metalloproteinase 12 and disrupting the glomerular basement membrane. Targeting GM-CSF to inhibit this axis reduced disease severity in mice, implicating this cytokine as a potential therapeutic target for patients with glomerulonephritis. —CM

11 April 2022 in Seminars in Immunopathology
Verified
Journal Article
Open access
PDF file
NANariaki Asada
Nariaki Asada
PGPauline Ginsberg
Pauline Ginsberg
NGNicola Gagliani
Nicola Gagliani
HMHans-Willi Mittrücker
Hans-Willi Mittrücker
UPUlf Panzer
Ulf Panzer
The identification of tissue-resident memory T cells (TRMcells) has significantly improved our understanding of immunity. In the last decade, studies have demonstrated that TRMcells are induced after an acute T-cell response, remain in peripheral organs for several years, and contribute to both an efficient host defense and autoimmune disease. TRMcells are found in the kidneys of healthy individuals and patients with various kidney diseases. A better understanding of these cells and their therapeutic targeting might provide new treatment options for infections, autoimmune diseases, graft rejection, and cancer. In this review, we address the definition, phenotype, and developmental mechanisms of TRMcells. Then, we further discuss the current understanding of TRMcells in kidney diseases, such as infection, autoimmune disease, cancer, and graft rejection after transplantation.

10 January 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
JRJan-Hendrik Riedel
Jan-Hendrik Riedel
LRLennart Robben
Lennart Robben
HPHans-Joachim Paust
Hans-Joachim Paust
YZYu Zhao
Yu Zhao
NANariaki Asada
Nariaki Asada
UPUlf Panzer
Ulf Panzer
Glucocorticoids remain a cornerstone of therapeutic regimes for autoimmune and chronic inflammatory diseases — for example, in different forms of crescentic glomerulonephritis — because of their rapid antiinflammatory effects, low cost, and wide availability. Despite their routine use for decades, the underlying cellular mechanisms by which steroids exert their therapeutic effects need to be fully elucidated. Here, we demonstrate that high-dose steroid treatment rapidly reduced the number of proinflammatory CXCR3 + CD4 + T cells in the kidney by combining high-dimensional single-cell and morphological analyses of kidney biopsies from patients with antineutrophil cytoplasmic antibody–associated (ANCA-associated) crescentic glomerulonephritis. Using an experimental model of crescentic glomerulonephritis, we show that the steroid-induced decrease in renal CD4 + T cells is a consequence of reduced T cell recruitment, which is associated with an ameliorated disease course. Mechanistic in vivo and in vitro studies revealed that steroids act directly on renal tissue cells, such as tubular epithelial cells, but not on T cells, which resulted in an abolished renal expression of CXCL9 and CXCL10 as well as in the prevention of CXCR3 + CD4 + T cell recruitment to the inflamed kidneys. Thus, we identified the CXCL9/CXCL10-CXCR3 axis as a previously unrecognized cellular and molecular target of glucocorticoids providing protection from immune-mediated pathology.

23 January 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
PGPauline Ginsberg
Pauline Ginsberg
UPUlf Panzer
Ulf Panzer
NANariaki Asada
Nariaki Asada
The discovery of tissue-resident memory T cells (TRM cells) reinterpreted the potential of human tissue-specific immunity. Following T cell receptor (TCR) activation and clonal expansion, effector T cells migrate to peripheral tissues where they remain long-term and differentiate to TRM cells after antigen clearance. This allows for prompt immunological responses upon antigen re-encounter. In addition to their protective properties in acute infections, recent studies have revealed that TRM cells might lead to aggravation of autoimmune diseases, such as lupus nephritis (LN) and anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (GN). These diseases present as proliferative and crescentic glomerulonephritis (cGN), which is a life-threatening condition leading to end-stage renal disease (ESRD) if left untreated. A better understanding of renal TRM cells might lead to identifying new therapeutic targets for relapsing autoimmune diseases of the kidney. In this review, we summarize the current knowledge of renal TRM cells and discuss their potential pathophysiological roles in renal autoimmune diseases.

20 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
HWHuiying Wang
Huiying Wang
JEJonas Engesser
Jonas Engesser
RKRobin Khatri
Robin Khatri
DSDarius P. Schaub
Darius P. Schaub
HPHans-Joachim Paust
Hans-Joachim Paust
NANariaki Asada
Nariaki Asada
In anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and systemic lupus erythematosus (SLE), glomerulonephritis is a severe kidney complication driven by immune cells, including T cells. However, the mechanisms underlying T cell activation in these contexts remain elusive. Here we report that in patients with AAV and SLE, type I interferon (IFN-I) induces T cell differentiation into interferon-stimulated genes-expressing T (ISG-T) cells, which are characterized by an elevated IFN-I signature, an immature phenotype, and cytotoxicity in inflamed tissue. Mechanistically, IFN-I stimulates the expression of interferon regulatory factor 7 (IRF7) in T cells, which in turn induces granzyme B production. In mice, blocking IFN-I signaling reduces IRF7 and granzyme B expression in T cells, thus ameliorating glomerulonephritis. In parallel, spatial transcriptomic analyses of kidney biopsies from patients with AAV or SLE reveal an elevated ISG signature and the presence of ISG-T cells in close proximity to plasmacytoid dendritic cells, the primary producers of IFN-I. Our results from both patients and animal models thus suggest that IFN-I production in inflamed tissue may drive ISG-T cell differentiation to expand the pool of cytotoxic T cells in autoimmune diseases.